Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-Small Cell Lung Cancer (NSCLC): A Phase II Study
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab
administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery
(adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a
type of immunotherapy that may enhance the ability of the immune system to fight off cancer.
The study will investigate the effects of pembrolizumab on the immune system and how certain
immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab.
Previous studies suggest that pembrolizumab could alter the immune cells in a way that the
the immune cells identify cancer cells. Pembrolizumab has been approved for the treatment of
advanced lung cancer, but is investigational in this setting.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.